Results from the phase 3 PEACE-3 study found that a combination therapy showed higher benefits for patients with bone ...

Local radiation therapy appears beneficial for men with bone metastatic hormone-sensitive prostate cancer (mHSPC).

Patients with metastatic prostate cancer may have improved survival outcomes after undergoing next-generation PSMA PET ...

Preliminary efficacy assessment from cohort 4 showed that all 3 participants had reductions in prostate-specific antigen (PSA) levels following 2 doses of 12GBq of 67 Cu-SAR-bisPSMA, with the largest ...

Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...

In metastatic hormone-sensitive prostate cancer (mHSPC), adding the radioligand 177 Lu-PSMA-617 (Pluvicto) to androgen ...

Survival after moderate HFRT in patients with high-risk prostate cancer was a secondary outcome of the randomized phase 3 Prostate Cancer Study 5 trial.

Nonlinear association seen for effective castration period with metastasis-free survival for any ADT duration.

A guideline panel indirectly studied cardiotoxicity among advanced prostate cancer treatments (mHSPC, mCRPC, CRPC).

Berlin: Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as ...

FRANKFORT, Ky. (WDRB) -- Two days after Kentucky Gov. Andy Beshear signed an executive order banning conversion therapy on minors, the Commonwealth Policy Center is speaking out against the order.